Michael Lahn

TGF-β Receptor Inhibitors Target the CD44high/Id1high Glioma-Initiating Cell Population in Human Glioblastoma

Judit Anido, Andrea Sáez‐Borderías, Alba Gonzàlez-Juncà et al. · Cancer Cell · 2010 · 576 citations · Full text

Medicine, Cancer Biology, Oncology +14

Blockade of TGF-β Signaling by the TGFβR-I Kinase Inhibitor LY2109761 Enhances Radiation Response and Prolongs Survival in Glioblastoma

Mengxian Zhang, Susanne Kleber, Manuel Röhrich et al. · Cancer Research · 2011 · 264 citations · Full text

Medicine, Oncology, Radiation Oncology +17

A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Robin Kate Kelley, Edward Gane, Eric Assénat et al. · Clinical and Translational Gastroenterology · 2019 · 245 citations · Full text

Medicine, Oncology, Pharmacology +17

First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma

Jordi Rodón, Michael A. Carducci, Juan Manuel Sepúlveda-Sánchez et al. · Clinical Cancer Research · 2014 · 232 citations

Medicine, Oncology, Pharmacology +13

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

Jonathan M. Yingling, William T. McMillen, Lei Yan et al. · Oncotarget · 2017 · 173 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +12